ClinicalTrials.gg
RecruitingNCT05564845BRICKUpdated Oct 4, 2022

Brain Structure and Neurocognitive Development in Sickle Cell Disease; a Longitudinal Cohort Study (BRICK Study)

An observational study in Brain Development Abnormality and Sickle Cell Disease, sponsored by Dr. Marjon H. Cnossen MD PhD. Recruiting at 2 sites in Netherlands. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Dr. Marjon H. Cnossen MD PhD · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
84
Ages
6 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Anemia, Sickle Cell with a site in Netherlands — 7 open to participants now, 12 under way, 4 of them phase 3. Anemia, Sickle Cell · Netherlands.

Started
2022
with 6 others
Observational
9 of 30
2 open now
Primary completion
2025-07
later than 4 of 11 live
Registered
19th of 30
by date
Lead sponsor
1 of 30
Dr. Marjon H. Cnossen MD PhD

Among the 30 studies in Anemia, Sickle Cell with a site in Netherlands, this one is one of 7 that started in 2022, is one of 9 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 19th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

7 of the 30 studies in Anemia, Sickle Cell with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 6 Years to 25 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Anemia, Sickle Cell with a site in Netherlands, or all of them as a file.
02

Study summary

Sickle cell disease (SCD) is an autosomal recessive red blood cell blood disorder. One especially vital organ affected in SCD is the brain. Individuals with SCD have an increased risk of both overt cerebral infarctions and silent infarctions. The latter are brain lesions without apparent neurological sequelae. Since cortical neurons in the brain lack the ability to regenerate, tissue damage accumulates throughout the already shortened lifespan of individuals with SCD, resulting in far-reaching consequences such as significant cognitive impairment. Currently, only hematological stem cell transplantation can halt the multiorgan tissue damage. However, the criteria to determine the timing of curative therapy do not center the brain, despite that subtle anomalies of this critical organ can have long-lasting consequences. Since it is not yet known whether brain tissue damage precedes, parallels, or lags behind non-brain tissue damage, it is critical to map these effects in youth with SCD. While importantly comparing images with a healthy reference population. Understanding how the brain is affected is critical for clinical decision making, such as timing of potentially curative interventions but also, to prevent long term irreversible brain damage in youth with SCD. In this study, a cohort of 84 SCD patients between the ages of 6 and 18 at baseline, will undergo MR imaging, neurological examination, neuropsychological assessment and blood sampling three times in total, with intervals of two years; results will be innovatively compared with children included in the Generation R population study (±8000 MRIs children and (young)adults) 6-20 years of age). Our hypothesis, based on the inability of the brain to generate new cortical neurons following cell death, is that brain function is impaired earlier than other organ systems and that there is an age-dependent limit in the brain's ability to remodel itself based on neuroplasticity.

Read the detailed description

Objective: The primary objective is to evaluate longitudinal developmental changes in brain structure in patients aged 6-18 years with SCD. The secondary objective is to analyze the longitudinal relations between biomarkers, demographic characteristics, brain structure, neurocognitive functioning, behavioral functioning and developmental changes in brain structure.

Study Design: Longitudinal cohort study (BRICK) with a duration of 4 years. Study population: Children and adolescents with sickle cell disease (SCD) of all genotypes (e.g. HbSS, HbSβº, HbSβ+, and HbSC) aged 6 -18 years. This will be compared to a cohort of healthy children and adolescents from Generation R.

Primary study endpoint:

  • Total white matter volume increase in children and adolescents with SCD Secondary study endpoints
  • Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization)
  • Incidence of stroke
  • Other forms complications due to SCD
  • Amount of hospital admissions, day care admissions (adult care only), crises at home, contact moments with the sickle cell center, ER visits
  • Biomarkers for anemia, hemolysis, inflammation and endothelial activation.
  • Behavioral functioning Nature and extent of the burden and risk associated with participation, benefit and group relatedness: By creating an advanced model for structural neurological, neurocognitive functioning in SCD, we will gain more insight into the pathophysiological origins and risk factors for SCD-related brain abnormalities. This will support development of preventive and supportive strategies as well as the initiation and evaluation of therapeutic interventions. Previous experience with the performance of brain MRI scans combined with recent research, indicates that the emotional burden placed on young children when undergoing a brain MR scan, are proportionate to the emotional burden placed on adults when they undergo a brain MR-scan. Furthermore, children will be offered the opportunity to become acquainted with the research procedure by witnessing an MRI scan session prior before participation.
03

Conditions studied

  • Brain Development Abnormality
  • Sickle Cell Disease

Browse trials for

Keywords

  • brain development
  • Sickle cell disease
04

Who can participate

Ages eligible
6 Years to 25 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children and adolescents diagnosed with SCD of all genotypes, treated at Erasmus MC and the Amsterdam UMC, ranging from 6 to 18 years at initiation of the study.

The clinical phenotype of SCD consists of a spectrum: From the patients with a high hemoglobin plus an absent or lower incidence of VOCs to the patients with a higher hemoglobin and a higher incidence of VOCs. We chose to include SCD patients of all genotypes, not only the HbSS and Hbẞ0 thalassemia, to cover the whole phenotypic range of SCD. This was chosen in order to infer the possible causes of an expected difference in white matter volume increase, like anemia and sickling-propensity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with SCD of all genotype between 6 and 18 at baseline

Exclusion criteria

Exclusion Criteria:

  • Parents/ guardians (in case of minors) or patients themselves (>16 years) unable to make an informed decision on participating in this study.

    • An abnormal brain MRI prior to initiation of the study due to non-SCD related causes.
    • for brain MRI per protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
84 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Severe SCD genotypes

    Children between 6 and 18 years of age of genotypes HbSS, HbSβº

    Diagnostic Test: MR scan of the brain · Diagnostic Test: Blood work · Diagnostic Test: Neurological examination · Diagnostic Test: Neuropsychological assessment

  • Not severe SCD genotypes

    Children between 6 and 18 years of age of genotypes HbSβ+, and HbSC and more

    Diagnostic Test: MR scan of the brain · Diagnostic Test: Blood work · Diagnostic Test: Neurological examination · Diagnostic Test: Neuropsychological assessment

Interventions

  • Diagnostic testMR scan of the brain

    Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.

  • Diagnostic testBlood work

    Lab work for current lab values and biobanking

  • Diagnostic testNeurological examination

    Classical neurological examination

  • Diagnostic testNeuropsychological assessment

    Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults * Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA) * A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II) * Narrative memory * Word fluency * Route finding NEPSY-II * World Fluency * Additional Questionnaires (6-18 years): * Child Behavior Checklist (CBCL) * Teacher Report Form (TRF) * Youth Self Report (YSR) * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report) * Conners-3® • Additional Questionnaires (18+ years): * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70) * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70) * Conners' Adult ADHD Rating Scales (CAARS) Emma toolbox

06

What researchers measure

Primary outcomes

  1. mm3/time unit

    Total white matter volume increase in children and adolescents with SCD

    Time frame: 4 years

Secondary outcomes

  1. Full scale IQ (FSIQ)

    Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization)

    Time frame: 4 years

  2. Incidence of stroke

    Time frame: 4 years

  3. Other forms complications due to SCD

    Time frame: 4 years

  4. Amount of hospital admissions

    Time frame: 4 years

  5. Ld, bilirubin

    Hemolysis biomarkers

    Time frame: 4 years

  6. Times/year

    ER visits

    Time frame: 4 years

  7. Hb, Ht

    Biomarkers for anemia

    Time frame: 4 years

  8. T score metric: a score of 50 represents the mean score of a reference population and 10 is the standard deviation.

    Patient-Reported Outcomes Measurement Information System® (PROMIS) within domains such as fatigue, pain behavior, depression, anxiety

    Time frame: 4 years

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jul 2025, 36 months after the start.

Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Oct 4, 2022
StartActual
Jun 20, 2022
Primary completionEst.
Jul 1, 2025
CompletionEst.
Jul 1, 2025
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564845
Lead sponsor
Dr. Marjon H. Cnossen MD PhD
Responsible party
Dr. Marjon H. Cnossen MD PhD (Principal Investigator, Erasmus Medical Center) — Sponsor-investigator
First posted
Oct 4, 2022
Start date
Jun 20, 2022
Primary completion
Jul 1, 2025 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Oct 4, 2022

Study contacts

Aida Kidane
Contact
a.kidanegebremeskel@erasmusmc.nl
+3110-7036691
Marjon Cnossen
Contact
m.cnossen@erasmusmc.nl
+310-7036691

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion